



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

ATTORNEY DOCKET NO. CONFIRMATION NO. FIRST NAMED INVENTOR APPLICATION NO. FILING DATE 4260 WOLF-GEORG FORSSMANN P65678US0 09/582,328 07/19/2000 EXAMINER 06/30/2004 7590 MAYER, SUZANNE MARIE JACOBSON HOLMAN PLLC 400 SEVENTH STREET N.W. ART UNIT PAPER NUMBER SUITE 600 1653 WASHINGTON, DC 20004

DATE MAILED: 06/30/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	on No.	Applicant(s)	
Office Action Summary		09/582,3:	28	FORSSMANN ET AL.	
		Examine	•	Art Unit	
		Suzanne	M. Mayer	1653	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Fallure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
1) Responsive to communication(s) filed on					
2a) This ac	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.				
3)☐ Since to closed	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims					
4)  Claim(s) 41-60 is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.  5)  Claim(s) is/are allowed.  6)  Claim(s) is/are rejected.  7)  Claim(s) is/are objected to.  8)  Claim(s) 41-60 are subject to restriction and/or election requirement.					
Application Papers					
<ul> <li>9) The specification is objected to by the Examiner.</li> <li>10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).</li> <li>11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.</li> </ul>					
Priority under 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of: <ol> <li>Certified copies of the priority documents have been received.</li> <li>Certified copies of the priority documents have been received in Application No</li> <li>Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> </ol> </li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>					
2) Notice of Dra 3) Information [	erences Cited (PTO-892)  Infragerson's Patent Drawing Review  Disclosure Statement(s) (PTO-1449  Mail Date	(PTO-948) or PTO/SB/08)	4) Interview Summ. Paper No(s)/Mai 5) Notice of Informa 6) Other:		TO-152)

Application/Control Number: 09/582,328

Art Unit: 1653

## **DETAILED ACTION**

## Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in a reply to this action, to elect a single invention to which the claims must be restricted.

Group 1, claims 41-48 and 50-52 are drawn to a serine protease inhibitor according to various amino acid sequences drawn from SEQ ID NO's: 1-4 and 7-41 and medicaments and methods of use of said protease inhibitors used to treat various diseases.

Group 2, claims 49-51, 53, 55, 59 and 60 are drawn to DNA encoding serine protease inhibitors according to Group 1 and medicaments and methods of use of said DNA to treat various diseases.

Group 3, claim(s) 54, 56-58, drawn to anti-bodies or fragments thereof against epitopes of serine protease inhibitors of claim 41 and diagnostics and medicaments of said anti-bodies to treat various diseases.

2. The inventions listed as Groups 1-3 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons.

The technical feature linking Groups 1-3 is that they are linked to proteins that possess specific amino acid structural motif which specifically have a domain wherein there are four cysteines. Cys-1 and Cys-2 are separated by 13 amino acids to; Cys-2

Application/Control Number: 09/582,328

Art Unit: 1653

and Cys-3 are separated by 18 amino acids and Cys-3 and Cys-4 are separated by two amino acids.

However, the protein encoded by the ORF2 of the *comE* gene possesses this same motif (in Molecular Microbiology, 1993, 10(1), 99-111). This amino acid sequence possesses the same special technical feature of having a domain wherein there are four cysteines where there are separated by 13 amino acids to between cysteines, followed by a separation of 18 amino acids between the next cysteine and finally a separation of two amino acids between the next cysteine.

Therefore, the technical feature linking the inventions of Groups 1-3 does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not differentiate the claimed subject matter as a whole over the prior art. Since according to PCT Rule 13.2 the presence of such a common or corresponding special technical feature is an absolute prerequisite for unity to be established, and given that there does not appear to be any other technical feature common to the claimed subject matter as a whole which might be able to fulfill this role, the currently claimed subject matter lacks unity of invention according to PCT Rule 13.1.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement may be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Suzanne M. Mayer, Ph.D. whose telephone number is

Application/Control Number: 09/582,328 Page 4

Art Unit: 1653

571-272-2924. The examiner can normally be reached Monday to Friday from 8.30am to 5.00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SMM 24 June, 2004

ROBERT A. WAX
PRIMARY EXAMINER